{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:50:59Z","timestamp":1767135059989,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd008335","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T00:00:00Z","timestamp":1268784000000}}],"reference-count":72,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008335.pub2","type":"journal-article","created":{"date-parts":[[2010,3,16]],"date-time":"2010-03-16T07:46:30Z","timestamp":1268725590000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pegloticase for chronic gout"],"prefix":"10.1002","author":[{"given":"Amy","family":"Anderson","sequence":"first","affiliation":[{"name":"Minneapolis VA Medical Center and University of Minnesota; Medicine; One Veterans Drive Minneapolis MN USA 55417"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasvinder A","family":"Singh","sequence":"additional","affiliation":[{"name":"Birmingham VA Medical Center; Department of Medicine; Faculty Office Tower 805B 510 20th Street South Birmingham USA AL 35294"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3,17]]},"reference":[{"issue":"9","key":"10.1002\/14651858.CD008335.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD008335.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.aca.2009.06.001","article-title":"Fabrication of dissolved O2 metric uric acid biosensor using uricase epoxy resin biocomposite membrane","volume":"647","author":"Arora","year":"2009","journal-title":"Analytica Chimica Acta"},{"issue":"4","key":"10.1002\/14651858.CD008335.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1310\/hpj4404-340","article-title":"New drugs approved by the FDA: New dosage forms and indications approved by the FDA - Agents pending FDA approval. New drug or biologics license applications filed by manufacturer: Supplemental applications filed by manufacturer - Significant labeling changes or \"dear health care professional\" letters related to safety","volume":"44","author":"Baker","year":"2009","journal-title":"Hospital Pharmacy"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0004|cit4","unstructured":"Baraf HS Kim S Matsumoto AK Maroli AN Resolution of tophi with intravenous peg-uricase in refractory gout Conference proceedings 2005"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0005|cit5","unstructured":"Baraf HS Kim S Matsumoto AK Maroli AN Resolution of tophi with intravenous peg-uricase in treatment failure gout Conference proceedings 2006"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Baraf HS Becker MA EdwardS NL Gutierrez-Urena SR Sundy JS Treadwell EL Resolution of gouty tophi after twelve weeks of pegloticase treatment Conference Proceedings 2008","DOI":"10.1002\/art.23993"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0007|cit7","unstructured":"Baraf HS Becker MA EdwardS NL Gutierrez-Urena SR Sundy JS Treadwell EL Tophus response to pegloticase (PGL) therapy: Pooled results from GOUT1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials Conference proceedings 2008"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0009|cit9","unstructured":"Becker MA Treadwell EL Baraf HS Edwards NL Gutierrez-Urena SR Sundy JS Immunoreactivity and clinical response to pegloticase (PGL): Pooled data from GOUT1 and GOUT2, PGL phase 3 randomized, double blind, placebo-controlled trials Conference proceedings 2008"},{"issue":"8","key":"10.1002\/14651858.CD008335.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/art.20438","article-title":"Gout: on the brink of novel therapeutic options for an ancient disease","volume":"50","author":"Bieber","year":"2004","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008335.pub2-BIB0011|cit11","first-page":"422","article-title":"Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout","volume":"9","author":"Biggers","year":"2008","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"9","key":"10.1002\/14651858.CD008335.pub2-BIB0012|cit12","first-page":"1942","article-title":"Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies","volume":"29","author":"Bomalaski","year":"2002","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD008335.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2710.2008.00994.x","article-title":"Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach","volume":"34","author":"Campara","year":"2009","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0014|cit14","unstructured":"Cao Y. Meng X.Liu J Enteric coated preparation for controlling hyperuricemia and gout comprises coated capsule of uricase Patent"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Cleveland BM Leonard SS Klandorf H Blemings KP Urate oxidase knockdown decreases oxidative stress in a murine hepatic cell line Conference Proceedings 2009","DOI":"10.4161\/oxim.2.2.8372"},{"issue":"7","key":"10.1002\/14651858.CD008335.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/art.24617","article-title":"Severe gouty arthritis and mild neurologic symptoms due to F199C, a newly identified variant of the hypoxanthine guanine phosphoribosyltransferase","volume":"60","author":"Ea","year":"2009","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0017|cit17","unstructured":"Edwards NL Baraf HS Becker MA Gutierrez-Urena SR Sundy JS Treadwell EL Improvement in health-related quality of life (HRQL) and disability index in treatment failure gout (TFG) after pegloticase (PGL) therapy: pooled results from GOUT1 and GOUT2, phase 3, randomized double blind, placebo (PBO)-controlled trials Conference proceedings 2008"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0018|cit18","unstructured":"Fridolin I Jerotskaja J Lauri K Luman M Substance's i.e. uric acid, concentration measuring device for treating e.g. hyperuricemia, has data representing module for executing program for data representation, where module has data visualization module Patent"},{"issue":"1","key":"10.1002\/14651858.CD008335.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthrtiis Research and Therapy"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0020|cit20","unstructured":"George V Grujic D Khalaf N McGrath M Patel R Shenoy B Watson E New uricase composition, useful for treating a disorder associated with elevated uric acid concentration Patent"},{"issue":"3","key":"10.1002\/14651858.CD008335.pub2-BIB0021|cit21","first-page":"111","article-title":"Gout: New treatment for an old disease","volume":"16","author":"Gruber","year":"2009","journal-title":"Journal fur Mineralstoffwechsel"},{"issue":"2","key":"10.1002\/14651858.CD008335.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.rdc.2006.02.002","article-title":"Clinical Trials in Crystal Arthropathy","volume":"32","author":"Joseph-Ridge","year":"2006","journal-title":"Rheumatic Disease Clinics of North America"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0023|cit23","unstructured":"Liu G Yang Z Liu Q Wu X Liu M Lai Q New polyethylene glycol urate oxidase compound, useful for preparing drugs for treating and preventing gout, reducing the level of blood uric acid, preventing tumor lysis syndrome and improving kidney functions Patent"},{"issue":"12","key":"10.1002\/14651858.CD008335.pub2-BIB0024|cit24","first-page":"795","article-title":"[Urate oxidase in the treatment of gout and hyperuricemia]","volume":"37","author":"Louyot","year":"1970","journal-title":"Revue du Rhumatisme et des Maladies Osteo-Articulaires"},{"issue":"4","key":"10.1002\/14651858.CD008335.pub2-BIB0025|cit25","first-page":"169","article-title":"[Experimentation with urate oxidase]","volume":"26","author":"Louyot","year":"1971","journal-title":"Journal Belge de Rhumatologie et de Medecine Physique. Belgisch Tijdschrift Voor Reumatologie En Fysische Geneeskunde"},{"issue":"9","key":"10.1002\/14651858.CD008335.pub2-BIB0026|cit26","first-page":"1332","article-title":"NEW ORIENTATION OF TREATMENT OF GOUT - CLINICAL AND BIOLOGICAL STUDY ON URATE OXIDASE","volume":"16","author":"Mizon","year":"1971","journal-title":"Lille Medical"},{"issue":"9","key":"10.1002\/14651858.CD008335.pub2-BIB0027|cit27","first-page":"1332","article-title":"[New trend in gout treatment. Clinical and biological study of urate oxidase]","volume":"16","author":"Mizon","year":"1971","journal-title":"Lille Medical"},{"issue":"3","key":"10.1002\/14651858.CD008335.pub2-BIB0028|cit28","first-page":"551","article-title":"[Rasburicase for tophaceus gout treatment]","volume":"34","author":"Ribeiro","year":"2009","journal-title":"Acta Reumatol Port"},{"issue":"R2","key":"10.1002\/14651858.CD008335.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"R177","DOI":"10.1093\/hmg\/ddp369","article-title":"Recent insights into the pathogenesis of hyperuricaemia and gout","volume":"18","author":"Riches","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD008335.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MAJ.0b013e3181a3dc14","article-title":"Axial gouty arthropathy","volume":"338","author":"Saketkoo","year":"2009","journal-title":"American Journal of the Medical Sciences"},{"issue":"11","key":"10.1002\/14651858.CD008335.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Care & Research"},{"issue":"1","key":"10.1002\/14651858.CD008335.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"5","key":"10.1002\/14651858.CD008335.pub2-BIB0033|cit33","first-page":"40","article-title":"The diagnosis and treatment of gout","volume":"34","author":"Smith","year":"2009","journal-title":"US Pharmacist"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0034|cit34","unstructured":"Sundy JS Ganson N Kelly SJ Scarlett EL Hershfield MS A Phase I study of pegylated-uricase (Puricase (R) in subjects with gout Conference proceedings 2004"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0035|cit35","unstructured":"Sundy JS Becker MA Baraf HSB Barkhuizen A Moreland L Huang B A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and refractory gout Conference proceedings 2005"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0036|cit36","unstructured":"Sundy JS Becker MA Baraf HSB Barkhuizen A Moreland LW Huang B A phase 2 study of multiple doses of intravenous polyethylene glycol (PEG)-uricase in patients with hyperuricemia and treatment failure gout Conference proceedings 2006"},{"issue":"3","key":"10.1002\/14651858.CD008335.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD008335.pub2-BIB0038|cit38","first-page":"1370","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0039|cit39","unstructured":"Sundy JS Baraf HS Becker MA Edwards NL Gutierrez-Urena SR Treadwell EL Efficacy and safety of intravenous (IV) pegloticase (PGL) in subjects with treatment failure gout (TFG): Phase 3 results from GOUT1 and GOUT2 Conference proceedings 2008"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0040|cit40","unstructured":"Sundy JS Becker MS Huang WY Waltrip RW Chandraker AK Treatment Failure Gout: Efficacy and Safety of Pegloticase in Phase 3 Trials Conference proceedings 2009"},{"issue":"4","key":"10.1002\/14651858.CD008335.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jbspin.2009.05.006","article-title":"Gout Study Group: Update on hyperuricemia and gout","volume":"76","author":"Terkeltaub","year":"2009","journal-title":"Joint Bone Spine"},{"issue":"7","key":"10.1002\/14651858.CD008335.pub2-BIB0042|cit42","first-page":"606","article-title":"New gout treatment approved","volume":"66","author":"Traynor","year":"2009","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"4","key":"10.1002\/14651858.CD008335.pub2-BIB0043|cit43","first-page":"658","article-title":"Urate oxidase (rasburicase) for treatment of severe acute gout: a case report","volume":"27","author":"Wipfler-Freibmuth","year":"2009","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0044|cit44","unstructured":"Yue CS Marier J Huang B Alton M Maroli A Wright D Population pharmacokinetic and pharmacodynamic analysis of PEG-uricase in subjects with hyperuricemia and refractory gout Conference proceedings 2006"},{"issue":"6","key":"10.1002\/14651858.CD008335.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/0091270008317589","article-title":"Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout","volume":"48","author":"Yue","year":"2008","journal-title":"Journal of Clinical Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD008335.pub2-BIB0046|cit46","first-page":"2403","article-title":"Epidemiology of gout: is the incidence rising?","volume":"29","author":"Arromdee","year":"2002","journal-title":"Journal of Rheumatology"},{"issue":"7454","key":"10.1002\/14651858.CD008335.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD008335.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group","volume":"4","author":"Atkins","year":"2004","journal-title":"BMC Health Services Research"},{"issue":"4","key":"10.1002\/14651858.CD008335.pub2-BIB0049|cit49","first-page":"422","article-title":"Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout","volume":"9","author":"Biggers","year":"2008","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0050|cit50","unstructured":"Cates C Visual Rx NNT Calculator version 3 [Computer program]. Dr Chris Cates' EBM web site Available from http:\/\/www.Nntonline.Net\/visualrx\/, Accessed 13 February 2009"},{"issue":"2","key":"10.1002\/14651858.CD008335.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/BOR.0b013e328325bd94","article-title":"Update on emerging urate-lowering therapies","volume":"21","author":"Chohan","year":"2009","journal-title":"Current Opinion in Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD008335.pub2-BIB0052|cit52","first-page":"341","article-title":"Gout: epidemiology and lifestyle choices","volume":"17","author":"Choi","year":"2005","journal-title":"Current Opinion in Rheumatology"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0053|cit53","doi-asserted-by":"crossref","unstructured":"Deeks J Higgins J Altman D Chapter 9: Analysing data and undertaking meta-analyses, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008) The Cochrane Collaboration. Available from: www.cochrane-handbook.org. 2008","DOI":"10.1002\/9780470712184.ch9"},{"issue":"6","key":"10.1002\/14651858.CD008335.pub2-BIB0054|cit54","first-page":"801","article-title":"Gout: an update","volume":"76","author":"Eggebeen","year":"2007","journal-title":"American Family Physician"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis & Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD008335.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3899\/jrheum.090371","article-title":"Progress in measurement instruments in acute and chronic gout studies","volume":"36","author":"Grainger","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0057|cit57","article-title":"Chapter 8: Assessing risk of bias in included studies. . In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]","volume-title":"www.cochrane-handbook.org","author":"Higgins","year":"2008"},{"issue":"12","key":"10.1002\/14651858.CD008335.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.3899\/jrheum.080506","article-title":"Evaluation of an instrument assessing influence of Gout on health-related quality of life","volume":"35","author":"Hirsch","year":"2008","journal-title":"Journal of Rheumatology"},{"issue":"2008(2):CD00552","key":"10.1002\/14651858.CD008335.pub2-BIB0059|cit59","article-title":"Systemic corticosteroids for acute gout","author":"Janssens","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD008335.pub2-BIB0060|cit60","first-page":"481-91","article-title":"Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films","volume":"18","author":"Larsen","year":"1977","journal-title":"Acta Radiologic Diagnosis (Stockholm)"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar1907","article-title":"Epidemiology, risk factors, and lifestyle modifications for gout","volume":"8 Suppl 1","author":"Saag","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"(4):CD006190","key":"10.1002\/14651858.CD008335.pub2-BIB0062|cit62","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006190","article-title":"Colchicine for acute gout","author":"Schlesinger","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD008335.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout. OMERACT 9","volume":"36","author":"Schumacher","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0064|cit64","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch11","article-title":"Chapter 11: Presenting results and \u2018Summary of findings tables'","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 500 [updated February 2008]","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD008335.pub2-BIB0065|cit65","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 500 [updated February 2008]","author":"Sch\u00fcnemann","year":"2008"},{"issue":"6","key":"10.1002\/14651858.CD008335.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"706-20","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis & Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD008335.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2509","article-title":"Developments in the scientific and clinical understanding of gout","volume":"10","author":"So","year":"2008","journal-title":"Arthritis Research and Therapy"},{"issue":"3","key":"10.1002\/14651858.CD008335.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD008335.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","article-title":"Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study","volume":"58","author":"Sundy","year":"2008","journal-title":"Arthritis and Rheumatism"},{"issue":"17","key":"10.1002\/14651858.CD008335.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Clinical practice. Gout","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008335.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD008335.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/0091270008317589","article-title":"Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout","volume":"48","author":"Yue","year":"2008","journal-title":"Journal of Clinical Pharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008335.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T23:51:56Z","timestamp":1711324316000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008335.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,3,17]]},"references-count":72,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008335.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,17]]}}}